Santhera Pharmaceuticals Holding AG - ESG Rating & Company Profile powered by AI
The Sustainability score for Santhera Pharmaceuticals Holding AG indicates its reporting of the United Nations SDGs. Alternative corporations in the scoring industry group for Santhera Pharmaceuticals Holding AG are shown. This Disclosure rating covers seventeen UN Sustainable Development Goals including: 'Good Health & Wellbeing', 'Climate Action' and 'Partnerships for the Goals'.
Santhera Pharmaceuticals Holding AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.6; made up of an environmental score of 8.0, social score of 4.8 and governance score of 4.0.
5.6
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
579 | Tonix Pharmaceuticals Holding Corp | 5.7 | High |
579 | VIVA Biotech Holdings | 5.7 | High |
602 | Santhera Pharmaceuticals Holding AG | 5.6 | High |
602 | Celltrion Inc | 5.6 | High |
602 | Adaptimmune Therapeutics PLC | 5.6 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Santhera Pharmaceuticals Holding AG have an accelerator or VC vehicle to help deliver innovation?
Does Santhera Pharmaceuticals Holding AG disclose current and historical energy intensity?
Does Santhera Pharmaceuticals Holding AG report the average age of the workforce?
Does Santhera Pharmaceuticals Holding AG reference operational or capital allocation in relation to climate change?
Does Santhera Pharmaceuticals Holding AG disclose its ethnicity pay gap?
Does Santhera Pharmaceuticals Holding AG disclose cybersecurity risks?
Does Santhera Pharmaceuticals Holding AG offer flexible work?
Does Santhera Pharmaceuticals Holding AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Santhera Pharmaceuticals Holding AG disclose the number of employees in R&D functions?
Does Santhera Pharmaceuticals Holding AG conduct supply chain audits?
Does Santhera Pharmaceuticals Holding AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Santhera Pharmaceuticals Holding AG conduct 360 degree staff reviews?
Does Santhera Pharmaceuticals Holding AG disclose the individual responsible for D&I?
Does Santhera Pharmaceuticals Holding AG disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Santhera Pharmaceuticals Holding AG disclose current and / or historical scope 2 emissions?
Does Santhera Pharmaceuticals Holding AG disclose water use targets?
Does Santhera Pharmaceuticals Holding AG have careers partnerships with academic institutions?
Did Santhera Pharmaceuticals Holding AG have a product recall in the last two years?
Does Santhera Pharmaceuticals Holding AG disclose incidents of discrimination?
Does Santhera Pharmaceuticals Holding AG allow for Work Councils/Collective Agreements to be formed?
Has Santhera Pharmaceuticals Holding AG issued a profit warning in the past 24 months?
Does Santhera Pharmaceuticals Holding AG disclose parental leave metrics?
Does Santhera Pharmaceuticals Holding AG disclose climate scenario or pathway analysis?
Does Santhera Pharmaceuticals Holding AG disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Santhera Pharmaceuticals Holding AG disclose the pay ratio of women to men?
Does Santhera Pharmaceuticals Holding AG support suppliers with sustainability related research and development?
Does Santhera Pharmaceuticals Holding AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Santhera Pharmaceuticals Holding AG reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Santhera Pharmaceuticals Holding AG involved in embryonic stem cell research?
Does Santhera Pharmaceuticals Holding AG disclose GHG and Air Emissions intensity?
Does Santhera Pharmaceuticals Holding AG disclose its waste policy?
Does Santhera Pharmaceuticals Holding AG report according to TCFD requirements?
Does Santhera Pharmaceuticals Holding AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Santhera Pharmaceuticals Holding AG disclose energy use targets?
Does Santhera Pharmaceuticals Holding AG disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Santhera Pharmaceuticals Holding AG have a policy relating to cyber security?
Have a different question?
Potential Risks for Santhera Pharmaceuticals Holding AG
These potential risks are based on the size, segment and geographies of the company.
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.